Szałwińska P, Malecka-Wojciesko E. Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system. Gastroenterology Review/Przegląd Gastroenterologiczny. 2026;21(1):108-110. doi:10.5114/pg.2026.160317.
APA
Szałwińska, P., & Malecka-Wojciesko, E. (2026). Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system. Gastroenterology Review/Przegląd Gastroenterologiczny, 21(1), 108-110. https://doi.org/10.5114/pg.2026.160317
Chicago
Szałwińska, Patrycja, and Ewa Malecka-Wojciesko. 2026. "Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system". Gastroenterology Review/Przegląd Gastroenterologiczny 21 (1): 108-110. doi:10.5114/pg.2026.160317.
Harvard
Szałwińska, P., and Malecka-Wojciesko, E. (2026). Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system. Gastroenterology Review/Przegląd Gastroenterologiczny, 21(1), pp.108-110. https://doi.org/10.5114/pg.2026.160317
MLA
Szałwińska, Patrycja et al. "Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 21, no. 1, 2026, pp. 108-110. doi:10.5114/pg.2026.160317.
Vancouver
Szałwińska P, Malecka-Wojciesko E. Vedolizumab as a first-choice biological treatment of Crohn’s disease in a patient with paraganglioma of the nervous system. Gastroenterology Review/Przegląd Gastroenterologiczny. 2026;21(1):108-110. doi:10.5114/pg.2026.160317.
